FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

The FDA's internal documents indicate that peptides lack sufficient evidence of efficacy and safety, according to materials reviewed by the agency. An FDA advisory panel is scheduled to meet later this month to discuss regulatory access to peptides. Robert F. Kennedy Jr. has expressed support for peptide therapies. The documents do not specify which peptides are under review or what specific regulatory changes the panel will consider.

Next story